Popular Trials
Behavioural Intervention
Electro Acupuncture for Breast Cancer
To evaluate the effectiveness of Electro acupuncture (EA) for treatment of persistent painful CIPN symptoms in patients with stages 1-3 breast cancer treated with docetaxel chemotherapy 6 months prior
Behavioural Intervention
NormaTec PCD (Peristaltic Pulse PCD) for Diabetic Polyneuropathy
The purpose of this study is to evaluate the efficacy of the NormaTec PCD, a non-invasive pneumatic compression device with the patented peristaltic pulse pneumatic waveform, in the treatment of Diabetic Peripheral Neuropathy (DPN). The study will compare treatment with a NormaTec PCD and a sham device to assess whether the NormaTec PCD improves the signs and symptoms of DPN.
Popular Filters
Trials for Diabetic Neuropathy Patients
Serotonin Receptor Agonist
Lorcaserin +1 More for Peripheral Neuropathy
This trial compares Lorcaserin and Duloxetine for treating nerve damage in colorectal cancer patients caused by chemotherapy. Lorcaserin may help with nerve function, and Duloxetine can help with pain and mood. Duloxetine is a medication approved for treating major depressive disorder, generalized anxiety disorder, and several chronic pain conditions, including chemotherapy-induced peripheral neuropathy.
Vitamin Supplement
Metanx for Diabetic Neuropathy
The objectives of the MEDIAN study are to evaluate the short-term and long-term safety and nutritional benefits of Metanx® versus placebo in subjects with mild to moderate diabetic peripheral neuropathy (DPN). Short-term effects will be evaluated during the first 16 weeks of treatment, and long-term effects will be evaluated over the duration of a 48 week treatment period.
Trials for Peripheral Nerve Injury Patients
PEG-mediated Fusion
PEG Fusion for Peripheral Nerve Injury
This trial is testing whether a reagent called PEG fusion is safe for promoting nerve regeneration in humans. The trial will establish safety data and examine the effect of PEG fusion on clinical outcomes including recovery of sensory and motor function.
Growth Hormone Releasing Factor
Tesamorelin for Peripheral Nerve Injury
This trial tests tesamorelin, a drug that increases growth hormone, to help patients with repaired ulnar nerve injuries recover better. The study will compare the recovery of those taking tesamorelin over a year. The goal is to see if tesamorelin improves nerve healing and function. Tesamorelin has been shown to reduce visceral fat and improve lipid profiles in patients with HIV-associated lipodystrophy.
Trials With No Placebo
PEG-mediated Fusion
PEG Fusion for Peripheral Nerve Injury
This trial is testing whether a reagent called PEG fusion is safe for promoting nerve regeneration in humans. The trial will establish safety data and examine the effect of PEG fusion on clinical outcomes including recovery of sensory and motor function.
View More Related Trials
Frequently Asked Questions
Introduction to peripheral neuropathy
What are the top hospitals conducting peripheral neuropathy research?
Finding effective treatments for peripheral neuropathy, a condition characterized by nerve damage that often leads to pain and numbness in the extremities, is a pressing challenge. However, several renowned medical centers are stepping up to the plate with ongoing clinical trials. In Clermont, Florida, South Lake Pain Institute is at the forefront of research with three active trials focused on peripheral neuropathy. Although they have yet to conduct any previous studies in this field, their dedication to advancing knowledge and treatment options is commendable. Similarly dedicated is M D Anderson Cancer Center in Houston, which also has three ongoing trials dedicated specifically to peripheral neuropathy but lacks any past investigations recorded. The University of California in San Diego joins this pursuit as well and currently has two active clinical trials addressing peripheral neuropathy; similar to the other hospitals mentioned here it also hasn't conducted past activities related directly.Closer towards East Coast resides Mount Sinai School of Medicine located within New york City limits -where researchers are exploring innovative solutions through two existing clinical tests targeted specifically towards patients suffering fromperipheral neuropathic symptoms showing hopefulness spirit despite not having ventured into such explorations prior.All the way across the country at University of Washington Medical Center located within Seattle territory , there are additional efforts being made.They currently hold two active clinical attempts hopingto find breakthroughs while simultaneously creating a benchmark record since there haven't been any investigations conducted previously regarding these cases.
These medical institutions serve as beacons of hope for those living with peripheral neuropathy by actively seeking new ways to alleviate their symptoms and improve their quality of life.With each trial comes an opportunity for groundbreaking discoveries that could revolutionize how we approach and manage this complex condition nationwide.Locations might differ from one another geographically but unitedly represent commitment towards enhancing patient care on national scale
Which are the best cities for peripheral neuropathy clinical trials?
When it comes to peripheral neuropathy clinical trials, several cities have emerged as leading centers for research and development. Houston, Texas and Atlanta, Georgia both offer 10 active trials investigating treatments such as Engensis, Duloxetine, Docetaxel, and Transcutaneous Electrical Nerve Stimulation. New york City follows closely behind with 9 ongoing studies exploring options like NRD135SE.1 and VX-548. Additionally, Chicago in Illinois and Anchorage in Alaska each host 8 active trials focused on various treatment modalities including Brief Electrical Stimulation Therapy and Docetaxel. These cities provide individuals suffering from peripheral neuropathy access to cutting-edge clinical trials that are essential for advancing the field of neurology and improving patient outcomes.
Which are the top treatments for peripheral neuropathy being explored in clinical trials?
Clinical trials are paving the way for new treatments to combat peripheral neuropathy, a condition that affects the nerves outside of the brain and spinal cord. One promising contender in this arena is NTX-001. This innovative treatment is currently being explored in two active clinical trials dedicated specifically to peripheral neuropathy. Since its introduction in 2020, it has already made an impact with its inclusion in two all-time trials focused on this debilitating condition. As researchers delve deeper into understanding and addressing peripheral neuropathy, NTX-001 demonstrates potential as a game-changer in providing relief for those suffering from this nerve disorder.
What are the most recent clinical trials for peripheral neuropathy?
Recent clinical trials have shown promising advancements in the field of peripheral neuropathy, offering hope to those affected by this condition. One such trial investigated the use of fish oil concentrate in oral capsule form as a potential treatment option. The results from Phase 1 and Phase 2 trials have sparked enthusiasm within the medical community. Additionally, cryocompression therapy, tested through a Phase 3 trial known as Arm 1, has demonstrated encouraging outcomes for peripheral neuropathy patients. Another notable study explored the efficacy of NTX-001—a development that could potentially pave the way for new therapeutic approaches. Moreover, ATX01 10% has exhibited promise in its ability to alleviate symptoms associated with peripheral neuropathy during Phase 2 trials. Lastly, focal vibration therapy showcased positive responses throughout its initial phase of testing—indicating potential benefits for individuals suffering from this condition. With these recent advances in research and treatment modalities, prospects are brightening up for individuals managing peripheral neuropathy.
What peripheral neuropathy clinical trials were recently completed?
Recently completed clinical trials in peripheral neuropathy have made significant strides in the search for effective treatments. These studies focus on understanding and managing this condition that affects the nerves outside of the brain and spinal cord. Notably, a trial evaluating the efficacy of Nerve Growth Factor (NGF) inhibitors was recently concluded, offering potential new avenues for therapeutic intervention. Further advancements were seen in a trial investigating stem cell therapy as a possible treatment option. The completion of these innovative trials demonstrates ongoing efforts to alleviate the burden faced by individuals living with peripheral neuropathy and brings hope for improved management strategies in the future.